Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits

Executive Summary

Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q4 2018
Biogen To Launch Phase III Alzheimer’s Prevention Study
Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis
Novartis’ Data-Centric R&D Strategy Adds Pact With UK-based Big Data Institute
Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances
Novartis Gives Up On Rituxan Biosimilar For US Market
Eight Things To Know From Novartis' Third Quarter Call
Alarm As Novartis Exits Antibiotics Space
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124333

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel